CZ1S

CZ1S is a long-acting triple agonist targeting the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon receptor (GCGR). Developed by Zhejiang Cuize Pharmaceutical Technology, it is designed for the treatment of metabolic disorders such as obesity and type 2 diabetes. By simultaneously activating these three pathways, CZ1S aims to provide superior weight loss and glycemic control compared to single or dual agonists. The GLP-1 and GIP components enhance insulin secretion and suppress appetite, while the glucagon component increases energy expenditure and improves lipid metabolism. It is currently undergoing Phase 1 clinical evaluation in healthy volunteers to assess safety, tolerability, and pharmacokinetics.

Other names

CZ1S injectionCZ-1S injectionCZ 1S injection